IRIS Accounts Production v25.4.12.37 03599818 Board of Directors 1.10.24 30.9.25 30.9.25 false true false false true false Fair value model iso4217:GBP iso4217:USD iso4217:EUR xbrli:shares xbrli:pure utr:tonnes utr:kWh 03599818 2024-09-30 03599818 2025-09-30 03599818 2024-10-01 2025-09-30 03599818 2023-09-30 03599818 2023-10-01 2024-09-30 03599818 2024-09-30 03599818 ns15:EnglandWales 2024-10-01 2025-09-30 03599818 ns14:PoundSterling 2024-10-01 2025-09-30 03599818 ns10:Director1 2024-10-01 2025-09-30 03599818 ns10:PrivateLimitedCompanyLtd 2024-10-01 2025-09-30 03599818 ns10:SmallEntities 2024-10-01 2025-09-30 03599818 ns10:AuditExempt-NoAccountantsReport 2024-10-01 2025-09-30 03599818 ns10:SmallCompaniesRegimeForDirectorsReport 2024-10-01 2025-09-30 03599818 ns10:SmallCompaniesRegimeForAccounts 2024-10-01 2025-09-30 03599818 ns10:FullAccounts 2024-10-01 2025-09-30 03599818 ns10:Director2 2024-10-01 2025-09-30 03599818 ns10:CompanySecretary1 2024-10-01 2025-09-30 03599818 ns10:RegisteredOffice 2024-10-01 2025-09-30 03599818 ns5:CurrentFinancialInstruments 2025-09-30 03599818 ns5:CurrentFinancialInstruments 2024-09-30 03599818 ns5:ShareCapital 2025-09-30 03599818 ns5:ShareCapital 2024-09-30 03599818 ns5:RevaluationReserve 2025-09-30 03599818 ns5:RevaluationReserve 2024-09-30 03599818 ns5:RetainedEarningsAccumulatedLosses 2025-09-30 03599818 ns5:RetainedEarningsAccumulatedLosses 2024-09-30 03599818 ns5:ComputerEquipment 2024-10-01 2025-09-30 03599818 ns5:FurnitureFittings 2024-09-30 03599818 ns5:ComputerEquipment 2024-09-30 03599818 ns5:FurnitureFittings 2024-10-01 2025-09-30 03599818 ns5:FurnitureFittings 2025-09-30 03599818 ns5:ComputerEquipment 2025-09-30 03599818 ns5:FurnitureFittings 2024-09-30 03599818 ns5:ComputerEquipment 2024-09-30 03599818 ns5:CostValuation 2024-09-30 03599818 ns5:DisposalsRepaymentsInvestments 2025-09-30 03599818 ns5:CostValuation 2025-09-30 03599818 ns5:WithinOneYear ns5:CurrentFinancialInstruments 2025-09-30 03599818 ns5:WithinOneYear ns5:CurrentFinancialInstruments 2024-09-30 03599818 ns5:RevaluationReserve 2024-09-30

REGISTERED NUMBER: 03599818 (England and Wales)

| UNAUDITED FINANCIAL STATEMENTS |

| FOR THE YEAR ENDED 30TH SEPTEMBER 2025 |

| FOR |

| HGH PARTNERSHIP LIMITED |

| HGH PARTNERSHIP LIMITED (REGISTERED NUMBER: 03599818) |

CONTENTS OF THE FINANCIAL STATEMENTS

FOR THE YEAR ENDED 30TH SEPTEMBER 2025

Page |

| Company Information | 1 |

| Balance Sheet | 2 |

| Notes to the Financial Statements | 4 |

| HGH PARTNERSHIP LIMITED |

COMPANY INFORMATION

FOR THE YEAR ENDED 30TH SEPTEMBER 2025

| DIRECTORS: | Mr C P D Johns

| Mrs S P Johns

| SECRETARY: | Mrs S P Johns

| REGISTERED OFFICE: | Mercury House

| 19-21 Chapel Street

| Marlow

| Bucks

| SL7 3HN

| REGISTERED NUMBER: | 03599818 (England and Wales)

| ACCOUNTANTS: | Richardson Jones

| Chartered Accountants

| Mercury House

| 19-21 Chapel Street

| Marlow

| Buckinghamshire

| SL7 3HN

| HGH PARTNERSHIP LIMITED (REGISTERED NUMBER: 03599818) |

BALANCE SHEET

30TH SEPTEMBER 2025

30.9.25 | 30.9.24 |

| Notes | £ | £ | £ | £

FIXED ASSETS

Tangible assets | 4 | 994 |  | 1,421 |  |

Investments | 5 | - |  | 10 |  |

Investment property | 6 | 1,670,000 |  | 1,406,788 |  |

1,670,994 |  | 1,408,219 |  |

CURRENT ASSETS

Stocks | 52,200 |  | 6,675 |  |

Debtors | 7 | 254 |  | 538,821 |  |

Cash at bank | 405,021 |  | 324,340 |  |

457,475 |  | 869,836 |  |

CREDITORS

Amounts falling due within one year | 8 | 2,212 |  | 4,552 |  |

NET CURRENT ASSETS | 455,263 |  | 865,284 |  |

TOTAL ASSETS LESS CURRENT LIABILITIES | 2,126,257 |  | 2,273,503 |  |

PROVISIONS FOR LIABILITIES | 53,358 |  | 64,490 |  |

NET ASSETS | 2,072,899 |  | 2,209,013 |  |

CAPITAL AND RESERVES

Called up share capital | 200 |  | 200 |  |

Revaluation reserve | 9 | 323,612 |  | 382,203 |  |

Retained earnings | 1,749,087 |  | 1,826,610 |  |

SHAREHOLDERS' FUNDS | 2,072,899 |  | 2,209,013 |  |

The company is entitled to exemption from audit under Section 477 of the Companies Act 2006 for the year ended 30th September 2025.

The members have not required the company to obtain an audit of its financial statements for the year ended 30th September 2025 in accordance with Section 476 of the Companies Act 2006.

The directors acknowledge their responsibilities for:

(a) | ensuring that the company keeps accounting records which comply with Sections 386 and 387 of the Companies Act 2006 and

(b) | preparing financial statements which give a true and fair view of the state of affairs of the company as at the end of each financial year and of its profit or loss for each financial year in accordance with the requirements of Sections 394 and 395 and which otherwise comply with the requirements of the Companies Act 2006 relating to financial statements, so far as applicable to the company.

| HGH PARTNERSHIP LIMITED (REGISTERED NUMBER: 03599818) |

BALANCE SHEET - continued

30TH SEPTEMBER 2025

The financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime.

In accordance with Section 444 of the Companies Act 2006, the Income Statement has not been delivered.

The financial statements were approved by the Board of Directors and authorised for issue on 30th March 2026 and were signed on its behalf by:

Mr C P D Johns - Director

| HGH PARTNERSHIP LIMITED (REGISTERED NUMBER: 03599818) |

NOTES TO THE FINANCIAL STATEMENTS

FOR THE YEAR ENDED 30TH SEPTEMBER 2025

1. | STATUTORY INFORMATION

| HGH Partnership Limited is a private company, limited by shares , registered in England and Wales. The company's registered number and registered office address can be found on the Company Information page.

2. | ACCOUNTING POLICIES

| Basis of preparing the financial statements

| These financial statements have been prepared in accordance with Financial Reporting Standard 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland" including the provisions of Section 1A "Small Entities" and the Companies Act 2006. The financial statements have been prepared under the historical cost convention as modified by the revaluation of certain assets.

| Tangible fixed assets

| Depreciation is provided at the following annual rates in order to write off each asset over its estimated useful life.

| Computer equipment | - | 25% on cost

| Investments in subsidiaries

| Investments in subsidiary undertakings are recognised at cost.

| Investment property

| Investment property is shown at most recent valuation. Any aggregate surplus or deficit arising from changes in fair value is recognised in profit or loss.

| Stocks and work in progress

| Work in progress is valued at the lower of cost and net realiisable value

| Pension costs and other post-retirement benefits

| The company makes contributions to its employees pension schemes. Contributions payable for the period are charged in the profit and loss account.

3. | EMPLOYEES AND DIRECTORS

| The average number of employees during the year was 2 (2024 - 2 ) .

4. | TANGIBLE FIXED ASSETS

Fixtures |

and | Computer |

fittings | equipment | Totals |

| £ | £ | £

| COST

| At 1st October 2024 | 538 |  | 3,314 |  | 3,852 |  |

| Additions | 206 |  | - |  | 206 |  |

| At 30th September 2025 | 744 |  | 3,314 |  | 4,058 |  |

| DEPRECIATION

| At 1st October 2024 | 426 |  | 2,005 |  | 2,431 |  |

| Charge for year | 151 |  | 482 |  | 633 |  |

| At 30th September 2025 | 577 |  | 2,487 |  | 3,064 |  |

| NET BOOK VALUE

| At 30th September 2025 | 167 |  | 827 |  | 994 |  |

| At 30th September 2024 | 112 |  | 1,309 |  | 1,421 |  |

| HGH PARTNERSHIP LIMITED (REGISTERED NUMBER: 03599818) |

NOTES TO THE FINANCIAL STATEMENTS - continued

FOR THE YEAR ENDED 30TH SEPTEMBER 2025

5. | FIXED ASSET INVESTMENTS

Shares in |

group |

undertakings |

| £

| COST

| At 1st October 2024 | 10 |  |

| Disposals | (10 | ) |

| At 30th September 2025 | - |  |

| NET BOOK VALUE

| At 30th September 2025 | - |  |

| At 30th September 2024 | 10 |  |

6. | INVESTMENT PROPERTY

Total |

| £

| FAIR VALUE

| At 1st October 2024 | 1,406,788 |  |

| Additions | 356,803 |  |

| Revaluations | (58,591 | ) |

| Reclassification/transfer | (35,000 | ) |

| At 30th September 2025 | 1,670,000 |  |

| NET BOOK VALUE

| At 30th September 2025 | 1,670,000 |  |

| At 30th September 2024 | 1,406,788 |  |

| Fair value at 30th September 2025 is represented by:

| £

| Valuation in 2018 | 56,853 |  |

| Valuation in 2019 | 40,000 |  |

| Valuation in 2021 | 80,592 |  |

| Valuation in 2022 | 49,758 |  |

| Valuation in 2023 | 125,000 |  |

| Valuation in 2024 | 30,000 |  |

| Valuation in 2025 | (58,591 | ) |

| Cost | 1,346,388 |  |

1,670,000 |  |

7. | DEBTORS: AMOUNTS FALLING DUE WITHIN ONE YEAR |

30.9.25 | 30.9.24 |

| £ | £

| Amounts owed by group undertakings | - |  | 356,821 |  |

| Other debtors | 254 |  | 182,000 |  |

254 |  | 538,821 |  |

| HGH PARTNERSHIP LIMITED (REGISTERED NUMBER: 03599818) |

NOTES TO THE FINANCIAL STATEMENTS - continued

FOR THE YEAR ENDED 30TH SEPTEMBER 2025

8. | CREDITORS: AMOUNTS FALLING DUE WITHIN ONE YEAR |

30.9.25 | 30.9.24 |

| £ | £

| Taxation and social security | 12 |  | 1,908 |  |

| Other creditors | 2,200 |  | 2,644 |  |

2,212 |  | 4,552 |  |

9. | RESERVES

Revaluation |

reserve |

| £

| At 1st October 2024 | 382,203 |  |

| Revaluation | (58,591 | ) |

| At 30th September 2025 | 323,612 |  |

10. | ULTIMATE CONTROLLING PARTY

| The company is ultimately controlled by the director Mr C Johns who own 70% of the issued share capital.